40.28MMarket Cap-381P/E (TTM)
0.3199High0.2230Low923.53KVolume0.3199Open0.2950Pre Close230.30KTurnover0.67%Turnover RatioLossP/E (Static)178.96MShares0.855052wk High-4.25P/B31.12MFloat Cap0.186652wk Low--Dividend TTM138.24MShs Float11.9000Historical High--Div YieldTTM32.85%Amplitude0.1320Historical Low0.2490Avg Price1Lot Size
BiomX Stock Forum
BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024
The findings will be presented in an oral presentation and an ePoster at the 47th European Cystic Fibrosis Conference, which is taking place June 5-8, 2024, in Glasgow, United Kingdom, and in a Rapid Fire oral presentation and a poster at the American Society for Microbiology (ASM) Microbe 2024 meeting, being held June 13-1...
$Wisa Tech get in why it's cheap
In a significant development in the biotech sector, BiomX Inc. (NYSEAMERICAN: PHGE), a clinical-stage microbiome company, has announced its entry into a merger agreement with Adaptive Phage Therapeutics (APT). The merger is complemented by a concurrent financing deal amounting to $50 million, marking a major milestone for both entities involved. $BiomX(PHGE.US)$